|Articles|March 28, 2019
BMS and Concerto HealthAI Agreement Accelerates Precision Oncology Innovations
Advertisement
The multi-year strategic agreement between Bristol-Myers Squibb and Concerto HealthAI announced will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials for precision treatment and improved patient outcomes.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results
2
Controlled Clinical Trials in Sub-Saharan Africa: A Winning Value Proposition
3
ACT Brief: FDA Approval of Oral Wegovy, 2025’s Most-Read ACT Coverage, and Data Quality as the Foundation for AI
4
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
5